Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Efizonerimod |
Synonyms | |
Therapy Description |
Efizonerimod (MEDI6383) is a fusion protein that binds to TNFRSF4 (OX40, CD134) and mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response (Journal of Clinical Oncology 33, no. 15_suppl (May 20 2015) 3056-3056, PMID: 29545330). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Efizonerimod | MEDI-6383|MEDI 6383|MEDI6383 | Efizonerimod (MEDI6383) is a fusion protein that binds to TNFRSF4 (OX40, CD134) and mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response (Journal of Clinical Oncology 33, no. 15_suppl (May 20 2015) 3056-3056, PMID: 29545330). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02221960 | Phase I | Durvalumab Efizonerimod | A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | Completed | USA | AUS | 0 |